CytoMed Therapeutics (GDTC) - 2024 Q4 - Annual Report

Exhibit 99.1 Net Loss: Excluding costs associated with being a public company listed on the NASDAQ Capital Market amounting to US1.66 million for the financial year ended December 31, 2024. Including these costs, the audited net loss was US3.03 million in 2023. The reduction was primarily due to the absence of initial public offerings ("IPO") related expenses, as well as lower ...